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Abstract
Substrate phosphorylation is a key modulator of signal transduction. Abnormal phosphorylation in vivo is implicated in many diseases including cancer, diabetes, and Alzheimer's disease.
Inhibitors of phosphate-recognizing proteins have potential as medicinal agents as well as tools to study phosphorylation pathways. A well-known and common inhibition strategy is to synthetically replace the labile phosphate moiety with a non-hydrolyzable phosphonate. Fully saturated, α-fluoro and α,α-difluorophosphonates are often effective phosphate bioisosteres and have been well studied. More recently α-brominated phosphonates have begun to emerge as inhibitors of phosphate recognizing enzymes, some of which operate by irreversible mechanisms. Herein we discuss the synthetic approaches to aliphatic and benzylic α-bromophosphonates and their biological activities.
Introduction: Phosphonates and α α α α-halophosphonates as phosphate bioisosteres
Substrate phosphorylation is a pivotal modulator of cellular function through its regulation of signal transduction pathways. It is estimated that one-third of all cellular proteins are modified through phosphorylation, making this the second most prevalent post-translational modification after glycosylation. 1 Phosphorylation of target molecules is carried out by kinases, acting in opposition to phosphatases, which dephosphorylate these same targets. 2 A large number of kinases and phosphatases are found in humans which generate or modify phospho-serine, threonine, tyrosine, or histidine residues. 2, 3 Additionally, phosphorylation pathways on lipid-and carbohydrate-based substrates play fundamental biochemical roles in metabolic processing and α-carbon, thus making the phosphonate a more effective electronic isostere of the phosphate group. 12, 13 α-Fluorophosphonates also reduce the pKa of the phosphonic acid protons below physiological pH (pKa 2 ~5.6), restoring the group to the same charge state as a native phosphate (pKa 2 ~6.4) at physiological pH. 11, 12 Medicinal chemists have more recently exchanged fluorine for bromine to determine the activity of α-bromophosphonates as inhibitors. Typical C−X bond lengths within α-halophosphonate compounds are 1.41 Å (C−F), 14 1.79 Å (C−Cl), 15 and 1.93 Å (C−Br). 16 Thus, α-bromophosphonates may have different steric requirements than their fluoro-derived counterparts. Additionally, while the bromine atom does not offer the same electronegativity as fluorine, it may act as a good leaving group offering the potential to create covalent labels of enzyme active sites that contain potent nucleophiles. 17, 18 This unique combination of features makes α-bromophosphonates a useful tool for the medicinal chemist. Herein we will discuss the synthesis and examples of applications which have exploited α-bromophosphonate derivatives in biological studies.
Design, synthesis and evaluation of α α α α-bromophosphonates as bioactive compounds
α-Bromophosphonates were first described in the literature over 90 years ago. The earliest example of an α-bromophosphonate was isolated as an α,β-dibromo phosphonic acid intermediate (1, Fig. 1 ) which was decomposed in the presence of base to provide a β-bromo-α,β-unsaturated phosphonic acid.
chemistry, additional reports of the synthesis of α-bromophosphonates as synthetic targets began to emerge. Early examples of α-bromophosphonates appeared in a 1953 study of pKa values of α-substituted phosphonic acids (2) . 10 The pKa values of compound 2 were found to be 1.14 and 6.52, respectively, 20 indicating that the α-bromophosphonates provide a pKa lowering effect over CH 2 -phosphonates (pKa 2 ~7.6) which more closely matches the acidity of the phosphonate to that of naturally occurring phosphates. This also indicates that the α-bromophosphonate group is 10-fold more basic than the α-fluorophosphonate moiety.
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The first biological studies of alkyl α-bromophosphonates (3) were conducted with α-bromophosphonates tested as agricultural chemicals. These compounds were found to be active in killing worms, insects, and bacteria. 
Benzylic α α α α-bromophosphonates
Synthetic access to benzylic α-bromophosphonates (BBP) has been well studied, and these are generally easier to access than their aliphatic counterparts (Scheme 1). This functional group has been exploited as a bioisostere of phosphotyrosine residues in medicinal chemistry. We highlight examples of BBP in the literature, and discuss general strategies for their synthesis below.
Synthetic approaches to BBP
Installation of bromine at the α-position of benzylic phosphonates is usually conducted through one of two general approaches, either (i) direct bromination or (ii) bromination of an α-hydroxy benzylphosphonate (Scheme 1b).
Scheme 1 a)
A generic benzylic α-bromophosphonate (BBP). b) Synthetic strategies for obtaining BBPs.
A summary of reported conditions used through pathway i (Scheme 1b) is given in Table 1 . The fully saturated phosphonate precursor is typically converted to the α-bromophosphonate through either radical bromination using N-bromosuccinimide (entries 1−4, Table 1 ) or through deprotonation of the α-proton to form a phosphorus-stabilized carbanion that is subsequently quenched with an electrophilic bromine source (entry 5, Table 1 ). Benzyl diethylphosphonate was subjected to three equivalents of lithium hexamethyldisilazide (LiHMDS) at −78 °C and the phosphorus-stablized anion was quenched with trimethylsilyl chloride (TMSCl) to temporarily install a TMS group at the α position in situ (entry 5). Under these conditions, a second deprotonation occurred simultaneously which was subsequently quenched with an electrophilic bromine source, 1,2-dibromotetrachloroethane (TCDBE). The reaction was then warmed to 0 °C and lithium ethoxide was added to cleave the TMS group, furnishing the BBP adduct in good yield. Importantly, for all entries in Table 1 , a 1:1 mixture of diastereomers at the α position is expected in the absence of any directing groups.
The phosphorous-stabilized α-carbanion (Scheme 2) has been examined by several groups. The pKa of the alkyl phosphonate α proton is relatively high (~29) 22 and deprotonation requires the use of a strong and non-nucleophilic base to produce the anion. 12 Cantat et al. confirmed that anionic C−P bonds are shorter than C−P bonds of the corresponding saturated compounds using crystallography. Computational analysis suggested stabilization of the anion through hyperconjugation resulting from p(C)→σ * (P−O) donation. It was concluded that contact with the metal cation is shared between the O=P−C atoms.
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Scheme 2 Deprotonation of a benzylic phosphonate to form a phosphorus-stabilized carbanion. The more common synthetic approach to form BBP is via an α-hydroxyphosphonate intermediate (pathway ii, Scheme 1b). This strategy typically involves milder conditions than the strong basic conditions required for formation of the α-carbanion. Shown in Scheme 3 is a general approach to the synthesis of the parent α-hydroxy adduct via Pudovik reaction. 30 In this transformation, a benzyaldehyde derivative is subjected to treatment with a deprotonated dialkylor diarylphosphite to furnish a diastereomeric mixture of the α-hydroxy analog.
Scheme 3
General form of the Pudovik reaction to generate a benzylic α-hydroxyphosphonate.
After obtaining the α-hydroxy precursor, the subsequent bromination reaction can be performed using a variety of conditions. Several methods used to achieve this transformation are summarized in Table 2 . Entries 1−8 are examples that achieved benzylic α-bromination with an electrophilic bromide source, with yields ranged from 42% to 100%. Entries 9−13 summarize conditions employed to obtain α-brominated phosphonates which were ultimately screened for activity against phosphate recognizing proteins. In all instances, the syntheses required no more than three chemical steps to obtain the target compound. Several analogs tested for activity from the references included in Table 2 are illustrated in Fig. 2 . We discuss the biological activity of these species below. however, it is not clear which of these pathways is specifically responsible for enzyme inactivation.
Scheme 4
Proposed mechanisms for covalent inhibition of a PTP by BBP: a) S N 2 displacement of bromide or b) intramolecular formation of a three-membered oxaphosphetane-like intermediate.
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Taylor et al. concluded that BBP 4 was an active site-directed covalent inhibitor of Yop51 at low mM concentration. 38 The absence of activity for probe 4 with alkaline phosphatase confirmed its specificity for PTPs. Zhang and coworkers expanded on this finding by constructing BBP analog 5, which was proposed as an activity-based proteomic probe (ABPP) to covalently tag phosphatase enzymes. 44, 45 Analog 5 built on the original BBP design by including an affinity tag, biotin, linked through the para-position of the aromatic ring. This modification enabled streptavidin to be used for detection of bioconjugates formed in the reaction of 5 with its targets.
Testing of analog 5 as an irreversible inhibitor of YopH, another PTP from Yersinia, showed that its activity was comparable to 4 ( Table 3 ). Compound 5 followed a similar inactivation time course to 4; however, it displayed 5-fold improved specificity for the enzyme. factor (PDGF) receptor signaling in an angiomyolipoma cancer cell model. 46 It is worth noting that these studies also raise the concern that, while extremely active, the α-BBP functional group alone does not provide specificity among different PTPs. 39 Fluorescent tags (9 and 10, Fig. 3 ) have been incorporated into α-BBP derivatives to detect PTPs in breast, lung, liver, ovarian and cervical cancer cell lines. The cell lines could be specifically labeled using these fluorescent probes at a concentration of 1 mM. These rhodamine-based regioisomers of α-BBP were isolated as a mixture and were not separated ( Fig. 3 ). These analogs offered a slight improvement in K I over analog 5 (Table 3) , but provided 1000-fold more sensitivity for detection of labeled enzyme. analysis with similar rate of inactivation to that of tripeptide 11. Importantly, they found that BrPmp in the context of the tripeptide had 4-fold increased specificity for the enzyme over BrPmp alone (Table 4) . 40 These results strongly suggest that an appropriate BrPmp peptide sequence could be used to target an individual PTP enzyme with high potency. The increased specificity of BrPmp in a peptide sequence provides support for this strategy as a means to design new inhibitors or probes that target individual PTPs. Benzylic α-bromophosphonates have been investigated as inhibitors of invasion and metastasis in cancer cell lines. α-Bromobenzylphosphocholine derivatives have been synthesized as potential inhibitors of autotaxin (ATX), which catalyzes the hydrolysis of lysophosphatidylcholine to form the bioactive lipid lysophosphatidic acid (LPA, Fig. 5 ). 48 ATX expression is upregulated in numerous cancers and has been shown to aid in tumor cell motility, resulting in implications for metastasis and invasion, as well as chemotherapy resistance. 41, 42, 49 LPA itself has demonstrated mitogenic, motogenic and anti-apoptotic properties that increase survival of carcinomas that use LPA in an autocrine and paracrine fashion. 41 Therefore, inhibitors of ATX provide an opportunity to reduce both ATX-induced and LPA-induced effects in cancer.
In 2008, ATX inhibitor S32826 (Fig. 5 ) was identified as the first nanomolar inhibitor of ATX (K i = 9.0 nM) 42 by high-throughput screening; however, it showed no inhibitory activity in vitro or in vivo. 41 Gupte et al. 41 was a much better inhibitor of ATX than the α-chloro derivative and was similar to the α-fluoro analog of the same scaffold. Interestingly, the analogous fully saturated phosphonate 12 ( 
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The Prestwich group tested an α-BBP derivative of S32826, compound 8. They argued that the lack of in vitro and in vivo activity was due to the low solubility of S32826. As a result, they opted to preserve the amide functionality and reduce the aliphatic chain length found in S32826.
One resulting compound, α-bromophosphonate 8, was found to inhibit ATX with nearly a 1000-fold improvement in potency (K i = 8.1 nM) over compound 7. This activity was also a 20-fold improvement over compound 12 and offered slight improvement over S32826. 42 These data suggest that the amide bond is crucial to potency toward ATX. We speculate that the limited activity of 12 and S32826 in vitro or in vivo could also be due to the reduced stability of these compounds, as hypothesized by Gupte et al. 41 Although there are an appreciable number of early synthetic examples that incorporate the α-BBP functionality, interest in their application to inhibit phosphate recognizing proteins was not explored until the mid-nineties. We believe that the examples discussed above highlight the untapped potential of benzylic α-bromophosphonates as irreversible inhibitors and probes of enzyme activity.
Aliphatic α α α α-bromophosphonates
There are far fewer synthetic examples of aliphatic α-bromophosphonates relative to α-benzylbromophosphonates; however, several biologically active analogs have been identified and tested. We summarize the synthesis and biological properties of these below.
Synthetic approaches
Synthesis of aliphatic α-bromophosphonates and α-halophosphonates is generally more difficult than that of α-BBPs. Interestingly, only a few synthetic reports have utilized an α-hydroxy precursor, which is the most commonly used parent compound for creating benzylic α-
bromophosphonates.
An early example of an aliphatic α-bromophosphonate synthesis was reported by Teulade and 53 To the best of our knowledge, the only other use of this methodology has been reported by Wnuk et al. Lithium−bromine exchange was used to convert saturated phosphonate 21 into α-bromo analog 22 as a precursor to radical cyclization (Scheme 7).
56
Scheme 7 An α-bromophosphonate as a precursor for radical cyclization. 56 Although methodology for obtaining aliphatic α-bromophosphonates via an α-hydroxy intermediate has not been explored as thoroughly as for the α-BBP moiety, it has been used with moderate to good yields. This conversion generally utilizes far milder conditions and provides the opportunity to obtain enantiopure products, which has not yet been achieved via lithium−bromine exchange.
Fu and co-workers conducted a methodological study on this transformation by bromination of a library of α-hydroxyphosphonates using mild conditions. Scheme 8 shows an example using an alkyl phosphonate. α-Hydroxypropylphosphonate 23 was brominated to obtain 24 using either PPh 3 /Br 2 and pyridine or PPh 3 , DDQ and Bu 4 NBr. 57 Mechanistic studies appear to rule out a radical pathway. 35 Analog 24 was used as an intermediate for subsequent fluorination via a phosphorus-stabilized carbanion using N-fluorobenzenesulfonimide (NFSI). Although the authors discussed the potential importance of these α-bromo-α-fluorophosphonate analogs as inhibitors of PTPs, they did not report biological testing.
57
Scheme 8 Electrophilic bromination of aliphatic α-bromophosphonates. 57 We focus now on examples of aliphatic α-bromophosphonates that have been assayed as inhibitors of phosphate recognizing proteins.
Aliphatic α α α α-bromophosphonate analogs of LPA.
Aliphatic α-bromophosphonates have been screened against phosphate recognizing proteins involved in the ATX−LPA pathway as anti-invasive and anti-metastatic agents (vide supra).
Prestwich and co-workers used an α-hydroxyphosphonate as the bromination precursor, which allowed for separation of the two epimers downstream (Scheme 10). Scheme 9 depicts the synthesis of α-bromophosphonates 27a and 27b. The parent α-hydroxy analog, 25, was treated with CBr 4 and PPh 3 to obtain alkyl α-bromo analog 26 in moderate yield. Biologically active phosphonates 27a and 27b were then obtained through acylation and phosphonate ester hydrolysis.
50

Scheme 9
The synthesis of biologically active α-bromo analogs 27a and 27b via α-hydroxy intermediate 25.
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By treating analog 25 with tert-butyldimethylsilyl chloride (TBDMSCl) under basic conditions, the resulting bulky siloxane product could be separated using flash chromatography. The TBDMS group was then cleaved under mildly acidic conditions to furnish the isolated α-hydroxy diastereomers (25-syn, 25-anti, Scheme 10). Scheme 10 The separation of α-hydroxy derivative 25 into its two diastereomers. 50 
α α α α-Bromophosphonates as inhibitors of cell invasion and metastasis
Aliphatic derivatives 27a and 27b were designed to target the G-protein coupled receptors (GPCRs) of LPA, which regulate cancer cell proliferation, invasion, and angiogenesis.
Compounds 27a and 27b were found to inhibit the four GPCRs screened, LPA 1 In a follow up study, Prestwich and coworkers tested the activity of diastereomeric α-bromo derivatives 27b-syn and 27b-anti in LPA−ATX signal transduction (Fig. 6) . They termed the collective syn and anti isomers of analog 27b as Br-LPA. In initial tests of the syn and antiisomers as separate compounds against LPA 1-4 receptors, both were found to be inhibitors of the GPCRs on their own, as had been predicted using molecular modeling. When screened against ATX, the anti-isomer (IC 50 = 22 nM) was determined to be a better inhibitor than the syn-isomer (IC 50 = 165 nM); however, both isomers inhibited ATX in a dose-dependent manner.
Furthermore, compounds 27b-syn, 27b-anti, and Br-LPA knocked out 98% of ATX activity at a concentration of 10 µM, but were only weakly active against platelet-activating LPA 5 . Both isomers also reduced MDA-MB-231 breast cancer cell invasion by ~50%; interestingly, the potency of the two diastereomers were not significantly different. 5 Follow-up studies have since found that Br-LPA can reduce tumor size in breast 5 and lung 59 tumor models in mice, and the compound had limited toxicity.
Br-LPA acts a substrate for LPA-induced behavior in neuropathic pain
Recently, the Rosenbaum group determined that LPA acts as a direct substrate for the TRPV1 ion channel. This channel is expressed in primary afferent nociceptors, and is sensitive to stimuli such as high temperature and low pH, which result in hyperalgesia in neuropathic pain.
Furthermore, Rosenbaum and coworkers showed that none of the LPA receptors discussed above are implicated in TRPV1 channel activation by LPA. In order to conclude that LPA receptors were not implicated in TRPV1-induced hyperalgesia, the authors compared LPA-induced activation of TRPV-1 to Br-LPA-induced activation. 
α α α α-Bromophosphonates on a carbohydrate scaffold
Phosphonate-based mimics of carbohydrates are also well known in the literature. 9 The first example of phosphonate synthesis in carbohydrates appeared over 50 years ago by Griffin and Burger when they synthesized glucose-6-phosphate analog, 29 (Fig. 7) . 61 Since that time, a range of carbohydrate phosphonate analogs have been targeted with general access available at all positions of pyranosides and furanosides (eg. 30). 9, 62, 63 Work to date towards glycosyl α-halophosphonate analogs has focused on the introduction of α-fluoro and α,α-difluorophosphonates at various positions of O-and C-glycosides (eg. 31). 12, 64 Important advances in the synthesis of both α-fluorinated and α,α-difluorinated glucosyl-6-phosphonates have been described by the Berkowitz group (Scheme 11). By treating α-hydroxyphosphonate 32 with diethylaminosulfur trifluoride (DAST) α-fluorophosphonate 33 was obtained in moderate yield, which could be resolved as a diastereomeric mixture by column chromatography.
obtain the related α,α-difluorophosphonate, Berkowitz and co-workers displaced triflate 34 using a phosphorus-stabilized carbanion, [diethylphosphono(difluoromethyl)]lithium, to provide α,α-difluorophosphonate 35 in good yield. 11,65−67 These examples illustrate the accessibility of α-fluorophosphonates; however, until recently there was no corresponding precedent to the α-brominated phosphonates on a carbohydrate scaffold. 
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We recently approached this problem by developing synthetic methods to access glucose-6-phosphate (G6P) derived α-bromophosphonates (36, Fig. 8 ) as inhibitors of glucose-6-phosphatase (G6Pase). 68 Specific inhibitors of G6Pase are of interest to both medicinal and biochemists 69 as G6Pase activity is upregulated in type II diabetes and no crystal structures of human G6Pase are available. 7, 70 G6Pase is known to contain a nucleophilic histidine and G6Pase analog 37 was hypothesized to be a potent or even irreversible inhibitor of the enzyme. (36) and targeted G6P analog 37.
68
Initial access to compound 37 was attempted via reduction of an α-bromo-α,β-unsaturatedphosphonate intermediate (38, Scheme 12) using standard hydrogenation conditions. This failed due to concomitant hydrogenolysis of the C−Br bond; 68 however, the α-bromo-α,β-unsaturated phosphonate scaffold has been shown to be biologically active in other systems 71 and was unprecedented in carbohydrates.
Scheme 12
Attempted access to α-bromo G6P analog 37 via standard olefinic reduction.
Biologically active E and Z isomers of α-bromo-α,β-unsaturated phosphonate 40 could be isolated via debenzylation using FeCl 3 .
68
Access to compound 37 was ultimately gained through a phosphorus-stabilized carbanion generated by n-BuLi that was quenched with Br 2 at −98 o C (Scheme 13). Deprotection of the 2-, 3-, and 4-OH groups and the phosphonate ester furnished target compound 37 in an additional two steps (not shown). Interestingly, the unique α,α-dibromophosphonate analog 43 could be isolated by subsequent treatment of the α-bromo analog 42 with LDA and quenching with Br 2 (Scheme 13). Similar methodology to provide an α,α-dibromophosphonate is known, but not on a carbohydrate scaffold.
72
Scheme 13 Partial synthesis of α-brominated phosphonate 37 with access to the α,α-dibromophosphonate 43.
68
Screening of target coumpound 37 displayed greater potency for G6Pase than the native G6P substrate in Wister rat liver microsomes; however, a 60 h incubation was required to achieve inhibition. The phosphonate ester 44 ( Fig. 9 ) also displayed potency that exceeded the K m of G6P, but with an incubation time of only 1 h. The α,α-dibromo analog 45 also displayed similar potency under the same conditions, indicating that α,α-dibromophosphonates are worthy of exploration as inhibitors of phosphate recognizing enzymes. Of note, the stereoisomers of α-bromo-α,β-unsaturatedphosphonate 40 also had similar potency against G6Pase.
To explore the activity of compound 44,
31
P NMR was used to confirm that the phosphonate ester could be hydrolyzed to compound 37 when incubated for 12 hours in rat liver microsomes.
This finding suggested that inhibition may be a result of phosphonic acid analog 37 after cleavage by a native esterase. There was no evidence of irreversible inhibition of G6Pase by any of the α-bromophosphonates screened, and future work will be required to confirm the mode of inhibition. Phosphonocarboxylates and bisphosphonates as bioisosteres of pyrophosphate have a host of medicinally important effects ranging from the prevention of bone resorption to cancer chemotherapy. 75, 76 Bisphosphonates are well known to have affinity for bone. 76 The reactivity of both bisphosphonate and phosphonocarboxylate analogs is dramatically increased over their monophosphonate counterparts. Additionally, both mono-and dibrominated bisphosphonates have been reported. We briefly highlight synthetic access to α-bromophosphonocarboxylates and α-bromobisphosphonates and offer a discussion of their applications in medicinal chemistry. Several researchers have utilized this methodology to obtain α-bromo and α,α-dibromophosphonoacetates on similar scaffolds with moderate to excellent yields. 78−86 Examples of access to brominated bisphosphonates using similar conditions are available.
87−89
Scheme 14 Access to α-bromo and α,α-dibromophosphonoacetates.
We note that the pKa of the α-proton in phosphonocarboxylates and bisphosphonates is significantly lowered, allowing for the formation of either a bisphosphonate-stablized carbanion or phosphorus−carboxylate-stablized carbanion to occur under milder conditions than in monophosphonates. Quenching the anion with an electrophilic bromine source subsequently provides the expected α-brominated phosphonocarboxylate and bisphosphonate analog. Suitable bases include n-BuLi, 90 LDA, 91 LiHMDS, 92 and NaH. 68,81,93−95 The McKenna group was able to develop α-halo derivatives of α-hydroxy compounds 53a and 53b (Scheme 15), which are known anti-osteoporotic agents that act through blockage of prenylation. These compounds are also known to bind bone minerals. 75, 76, 96 Protected benzylic bisphosphonates and phosphonocarboxylates were brominated via a stabilized carbanion generated by treatment with NaH and quenched with NBS. This strategy provided analogs 52a and 52b in good yields (Scheme 15). 75, 96 Unfortunately, testing of the biologically active, free acid form of α-bromo analogs 52a and 52b indicated they were generally less active than the previously studied α-OH analogs 53a and 53b. 75, 96 
Mono-and dibrominated polyphosphonates
Both nucleoside and non-nucleoside polyphosphonate analogues have been proposed for use in medicinal applications. We highlight the syntheses that incorporate an α,α-dibromophosphonate moiety representative of this class of molecules (Scheme 16). General access to these seemingly intricate α,α-dibromo polyphosphonate analogs begins from α,α-dibromo-diphosphonic acid (54) and a carbodiimide (CDI)-activated phosphonate (55 or 57). Yields are generally moderate, and both the adenine and guanine analogs of carbocyclic dinucleoside 57 were synthesized (e.g.
58)
. In all instances the NBu 4 + phosphonate salts were isolated. 
97−99
Non-nucleoside triphosphate analogs are inhibitors of terminal deoxynucleotidyl transferase (TDT), which has upregulated expression in leukemia. 98, 100 Arzmanov et al. screened dibromo species 56 against TDT but it was found to have lower affinity for TDT than the analogous P−CF 2 −P phosphonate or the P−O−P triphosphonate analog. 98 Carbocyclic dinucleoside polyphosphonates have shown activity against HIV reverse transcriptase-catalyzed DNA synthesis and hence demonstrate antiviral activity. Fig. 11) . 12 Analog 63 was tested as an inhibitor of purine nucleoside phosphorylase (PNP) which catalyzes the phosphorolysis of (deoxy)guanosine and (deoxy)inosine into guanidine and hypoxanthine. This class of inhibitors for PNP are of interest as potential immunosuppressive agents. 12 The corresponding fullysaturated phosphonate of compound 63 was found to inhibit human erythrocyte PNP with a K i of 174 nM, while 63 had substantially increased activity. 105 These examples demonstrate the potential of α-halogenated phosphonates as immunosuppressive agents, and the corresponding α-bromo phosphonate compounds remain to be explored.
97,99
Fig. 11
Examples of α-fluorinated methylenephosphonate-based nucleosides(tides).
More recently it has been demonstrated that β,γ-methylene-dGTP analogs can act as substrate mimics of dNTPs for DNA polymerase β. 106−109 Monobromo dGTP analog 66 was synthesized in one step by coupling N,N′-dicyclohexylcarbodiimide (DCC)-activated dGMP with α-bromodiphosphonic acid (65) in 40% yield (Scheme 17). This synthetic strategy mirrors that of the nucleosides presented above (Scheme 16). The dibromo dGMP analog has also been reported, which was accessed via phosphonic acid 54 in 40% yield (not shown). 107 To demonstrate the ability of β,γ-methylene-dGTP analogs to function as substrate mimics of DNA polymerase β, the authors obtained crystal structures of numerous halogenated β,γ-methylenedGTP−DNA polymerase β ternary complexes, including analog 66.
study the fidelity of DNA polymerase β by looking at specific alterations in the active site due to binding of foreign nucleoside analogs. 107, 109 Recently, these authors expanded the library of β,γ-methylene-dNTP to include halogenated thymidine and cytidine analogs. They showed that binding of analog 66 and its dibrominated counterpart, as well as and other halogenated β,γ-methylene dNTPs have tremendous effects on the transition state energies of DNA polymerase β-mediated catalysis. 110 These results certainly show promise for a broadened utility of β,γ-bromomethylene dNTP analogs to function as substrate mimics for other polymerases and other enzyme systems.
Scheme 17 Synthesis bromo-GTP analog 66 as a substrate for DNA polymerase β. 
Conclusions and outlook
There are a range of available methods to synthesize α-bromophosphonates, and these allow Page 38 of 48 Medicinal Chemistry Communications versatile access to this functional group from alkyl, α-hydroxy, or benzyl substituted phosphonate starting materials. The reports summarized here provide a survey of the known biological activities observed for α-bromophosphonates and α,α-dibromophosphonates. This functional group has become an important bioisostere of the phosphate moiety, which can be used in the development of inhibitors and probes of phosphate-recognizing proteins. The ability of α-bromophosphonates to act as specific covalent labels in PTP systems has enormous potential in the identification of new enzymes, and in the development of new specific inhibitors.
The scope of the inhibitor activity of α-bromophosphonates has recently been broadened to include GPCRs, ion channels, and glucose-6-phosphatase. The application of these compounds in mechanistic studies of enzymes, e.g. as dNTP mimics with polymerases, remains an area primed for expansion. The α-brominated phosphonates are an important functional group in the toolbox of medicinal chemists and chemical biologists.
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